• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Part 11 – Validation Models for Execution Infrastructures

Part 11 – Validation Models for

Execution Infrastructures

11.1 Validation Models for Data Set Selection Methods

11.1.1 First Joint Article Grok 4.1 and LPBI Group Proprietary Oncology Content – Validation Model for Text and Images published 12/15/2025 by Expert A, Expert B and Grok 4.1 by xAI

Module 1: Benchmarking NLP on Expert A: Expert Selected Data Set of 25 Oncology articles and 20 Images – Uplift for Module 1 by Grok’s 2025 NLP

Module 2: LLM and Causal Reasoning on Data Set in Module 1

  • Uplift by Grok’s New Dyads Discovery (NDD), and
  • Grok’s Launch of Triad Discovery Method (TDM)

>>> Major % Uplift by

2.1 Triad Method

2.2 Therapeutic MOA properties

2.3 Image analysis of histology & pathology

Module 3: Expert A: Expert Selection of 20 articles in Dominant Oncology Categories of Research (DCR)

20 articles across 3 categories in Oncology

  • Articles included in Module 1 (on Text and Images)
  • Articles not included in Module 1 (on Text)

>>> Major Triads discovery by Grok’s LLM and Casual Reasoning (on Text)

Module 4: Expert Selections of Chapters in e-Books (ESCB)

4.1 Expert A: Genomics, Series B, Volume 1, Chapter with 8 articles

4.2 Expert A: Immunology, Series D, Volume 3, Chapter with 8 articles

4.3 Expert B: Cardiovascular, Series A, Volume 4,

  • Translational Chapter – 11 articles
  • Regenerative Chapter – 11 articles

>>> Major Triads Discovery by Grok’s LLM and Causal Reasoning (on Text)

11.1.2 Second Joint Article Grok 4.1 and LPBI Group’s Expert B, forthcoming 2/15/2026 Proprietary Cardiovascular Content, Validation model for Audio, Text Images

Module 5: Expert B Selected a 13-article Series on Calcium role in Cardiac Functions

Module 6: Benchmark NLP + DL Wolfram vs Grok 4.1 on data of Module 5

Module 7: LLM and Causal Reasoning on Data of Module 5

Module 8: Expert B selects all or subset of Articles on Calcium in the Journal for Grok’s NLP, LLM and Causal Reasoning

Module 9: Expert B selects Chapter 18 on CVD Podcasts in IP Asset Class X: Library of Podcasts for Audio, Text, Images

Module 10: Grok 4.1 uses Data in Module 9 for Training a Multimodal Model using Audio, Text, Images

Module 11: Scoop.it mini vault: Expert B selected the earliest 88 articles placed in Three Journals on Scoop.it

Module 12: Grok 4.1 to develop 1.0 version of Hybrid Co-curation by Expert B and Expert B guiding Grok using Module 11 data for Training on Co-curation

 

11.2 Validation Model for Data Access Sequences prioritized by Executives for knowledge acquisition in Virtual Data Exposition about Acquisition Decision Making

11.2.1 Virtual Data Exposition of Endgame: Achievement of Gold & Silver Medals in “AI in Health”

  • Slide show of trophies:

>>> Modules 2,3,4

>>> Modules 6,7,8,9,12

  • Slide show of PORTFOLIO OF IP
• IP Asset Class I: Journal: PharmaceuticalIntelligence.com
6,250 scientific articles (70% curations, creative expert opinions.  30% scientific reports).
2.4MM Views, equivalent of $50MM if downloading an article is paid market rate of $30.
• IP Asset Class II: 48 e-Books: English Edition & Spanish Edition.
152,000 pages downloaded under pay-per-view. The largest number of downloads for one e-Publisher (LPBI)
https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss
• IP Asset Class III: 100 e-Proceedings and 50 Tweet Collections of Top Biotech and Medical Global Conferences, 2013-2025
https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/
• IP Asset Class V: 7,500 Biological Images in our Digital Art Media Gallery, as prior art
• IP Asset Class X: +300 Audio Podcasts: Interviews with Scientific Leaders
https://pharmaceuticalintelligence.com/biomed-audio-podcast-library-lpbi-group/
In addition, other five IP assets include the following:
• IP Asset Class VIII: ~9,000+ Subscribers to the Journal of 6,250 articles. Journal Ontology is extremely valuable as OM (Ontology Method) for LLM, ML, NLP
• IP Asset Class IV: Composition of Methods: SOP on How create a Curation, How to Create an electronic Table of Content (eTOC), work flows for e-Proceedings and many more, Part 1 to Part 13
https://pharmaceuticalintelligence.com/sop-web-stat/
https://pharmaceuticalintelligence.com/composition-of-methods-com/
• IP Asset Class VII: Royalties paid for pages downloaded from e-Books
• IP Asset Class VI: Bios of Experts as Content Creators
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
• IP Asset Class IX: INTANGIBLES: e-Reputation: +1,200 Endorsements, Testimonials, Notable followers on X.com: Editor-in-Chief Journal American Medical Association (JAMA), Broad Institute @MIT, Big Pharma, 500 CEOs of them 300 in Biotech are 1st connection on LinkedIn, and more indicators
https://pharmaceuticalintelligence.com/intangibles-cim/

Module 13: List of Slides Titles on PPT file

Slide 1 to Slide 28

  • On each Slide Title Slide there is a LIVE URL to Slide’s Body on WordPress

Module 14: List of Appendices Titles on PPT file

Appendix 1 to Appendix 32

  • On each Appendix Title Slide their is a LIVE URL to Appendix’s Body on WordPress

Module 15:

Body of each Slide Title Slide is on a Nested WordPress Page accessed by a LIVE URL on each Slide requires Password to be shared at the beginning of the Zoom

Module 16:

Body of each Appendix is on Nested, Nested WordPress Page accessed by a LIVE URL ( different than in Module 15) on each of the Appendix Title Slide requires Password SAME as in Module 15

Validation Model is designed to learn from the 1st Zoom session the following points:

  1. what are the knowledge priorities of the Executives:

Priority A: Endgame

Priority B: Slides Titles – All Topics covered

Priority C: Appendices Title – All Options for Deep Dive Data

Priority D: BODY of each Slide

Priority E: BODY of each Appendix

  1. to use lessons learned for application in forthcoming Zoom sessions with same Executives

Module 17: Validation Methods:

17.1 Text Analysis of the Script of the RECORDED Zoom session

17.2 cluster of questions asked

17.3 sequence of questions

Module 18: Comparison of Priorities in Assumptions: Module 16: A,B,C,D,E vs the results obtained in Module 17: 17.1, 17.2, 17.3

Module 19: Results of Module 17 applied for architecture design of Virtual Content Exposition for 2nd Zoom

19.1

IF

Module 18 captured that Each Executive had a different Priority list

THEN

Each Executive will receive a Personal Slide Deck

IF

Module 18 reveals Clusters of executives for clusters of Close priorities

THEN

the 2nd session will aggregate topics in different combination than the one followed by next.

Scenario Guidance #1:

  • IF the interest focus is on
  1. Universes of Intelligence as mirrored in Journal’s Ontology

or

  1. IP Assets by Class

or

  1. Application potential of Universes of Intelligence

or

  1. Leverage of vertical integration

 

  • THEN we would prepare custom-tailored responses

 

Scenario Guidance #2:

IF

The interest is to start with

  • What it takes to achieve Transfer of Ownership?

THEN

The discussion will focus of the details of

  • Slides 21, 22, 23 – only

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
    • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI in Health, Life Sciences & BioPharma June 15, 2026
    • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
    • A Systematic Analysis of Competitive Dynamics in the AI Revolution — Strategic Relevance to LPBI Group’s Mission – Alex Wissner-Gross Daily Newsletters by KOL (March 1 – June 10, 2026, to be extended to Present) June 11, 2026
    • In Memoriam: Professor Yitzhak Apeloig, President and Distinguised Professor of the Technion June 4, 2026
    • Top VC Investors in AI / Health AI in 2026 May 26, 2026
    • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UC, Berkeley, 1983. January 31, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


%d